SUPPLEMENTARY MATERIALS

Fluorescence-based co-detection with protein markers reveals distinct cellular compartments for altered microRNA expression in solid tumors

Lorenzo F. Sempere (1,*), Meir Preis (1), Todd Yezefski (1), Haoxu Ouyang (1,2), Arief A. Suriawinata (3), Asli Silahtaroglu (4), Jose R. Conejo-Garcia (1,5), Sakari Kauppinen (6,7), Wendy Wells (3), Murray Korc (1,2)

Supplementary figures and tables:

| Supplementary Figure 1: | Parameter optimization of ISH method. | | | | |
|-------------------------|--|--|--|--|--|
| Supplementary Figure 2: | Sensitivity of detection is enhanced by incorporation of two terminal hapten moieties. | | | | |
| Supplementary Figure 3: | Raw data and signal quantification analysis of image panels shown in Figure 2. | | | | |
| Supplementary Figure 4: | Raw data and signal quantification analysis of image panels shown in Figure 3. | | | | |
| Supplementary Figure 5: | Raw data and signal quantification analysis of image panels shown in Figure 4. | | | | |
| Supplementary Figure 6: | Co-detection of microRNAs, ribosomal RNA and protein markers in breast tissue. | | | | |
| Supplementary Figure 7: | miR-21 and PTEN expression in matched normal and tumor tissues. | | | | |
| Supplementary Table 1: | miRNA probe sequences and hybridization conditions. | | | | |
| Supplementary Table 2: | List of antibodies and conditions. | | | | |
| Supplementary Table 3: | Preparation of tyramide fluorescent substrates and conditions for TSA reaction for microRNA and protein detection. | | | | |



Supplementary Figure 1. Parameter optimization of ISH method. Consecutive 4- μ m normal FFPE breast tissue sections were used to detect miR-205 using our standard ISH assay. miR-205 signal was revealed by sequential TSA reactions with FITC-tyramine (green). Deviation from the standard protocol (10 pmol of LNA-modified DNA probe against miR-205, 20 min PK digestion, 1° rabbit anti-Fluorescein/HRP antibody, 2° anti-rabbit/HRP antibody for sandwich amplification, and 15 min TSA reaction) is noted above each image. Upper panel displays raw fluorescent image of normal breast epithelial structures and lower panel displays a heat map generated by Image-Pro Plus software in which each color class highlights pixels within the indicated fold-change range of signal intensity above background (See color scale).



Supplementary Figure 2. Sensitivity of detection is enhanced by incorporation of two terminal hapten moieties. a-h) Probes with one or two hapten moieties were used to co-detect miR-21 and U6 snRNA in consecutive matched normal (a & b) and tumor (d & e, g & h) tissue using our standard ISH assay. A TSA reaction with green fluorochrome substrate (FITC) was carried out to reveal miR-21 expression. Then, HRP was inactivated with H₂O₂ and a second TSA reaction with red fluorochrome substrate (Rhodamine red) was carried out to reveal U6 expression. RNA detection was highly improved by the use of probes 5'- and 3'- terminally tagged with hapten moieties, please compare images of upper and middle panel, which were all captured with the same exposure and gain settings. c,f) Signal for miR-21 on images b and e were quantitated with Image-Pro Plus and displayed as colorized intensity classes on c and f, respectively. Intensity range of yellow class was set to include all fluorescent objects in normal tissue, pink and red classes encompass fluorescent objects with higher intensity than yellow class. i) Histogram displays signal intensity per pixel within a representative area of normal and tumor tissue. Pink class mainly includes signal within cancer cells (ICa) and red class within tumor-associated fibroblasts (TAF).



Supplementary Figure 3. Primary data and signal quantification analysis of image panels shown in Figure 2. a) Matching raw fluorescent images of those displayed in Figure 2. Images were captured with an F-view II monochrome camera (Olympus) as grayscale TIF files and later colorized. Color scheme of individual images differs from the one shown in Figure 2; this was needed to conduct expression analysis of indicated miRNAs and proteins. b) Green, red and blue images were merged using the combine channels function from cellSens software package and saved as RGB TIF files. Once on Image-Pro software, a free shape line trace (line tool profile analysis) was used to quantitate intensity of indicated miRNA and protein expression. Merged RGB may be shifted with respect to raw images to fully display the line trace. Background intensity was subtracted from the intensity values and intensity values were normalized setting the point with maximum intensity at 100 and calculating other value in relation to this reference. Square dot indicates the beginning of the line profile reading and it corresponds to the most left value of the graph panels.



Supplementary Figure 4. Primary data and signal quantization analysis of image panels shown in Figure 3. a) Matching raw fluorescent images of those displayed in Figure 3. Images were captured with an F-view II monochrome camera (Olympus) as grayscale TIFF files and later colorized. Color scheme of individual images differs from the one shown in Figure 3; this was needed to conduct miR-155 (green), CK19 (red) and CD45 (blue) expression analysis with Image Pro-Plus software. b) miR-155, CK19 and CD45 images were merged using the combine channels function from cellSens and saved as RGB TIF files. Once on Image Pro, a free shape line trace (line tool profile analysis) was used to quantitate intensity of miR-155, CK19 and CD45 expression. Background intensity was subtracted from the intensity values and intensity values were normalized setting the point with maximum intensity at 100 and calculating other value in relation to this reference. Square dot indicates the beginning of the line profile reading and it corresponds to the most left value of the graph panels.



Supplementary Figure 5. Primary data and signal quantization analysis of image panels shown in Figure 4. a) Matching raw fluorescent images of those displayed in Figure 4. Images were captured with an F-view II monochrome camera (Olympus) as grayscale TIFF files and later colorized. Color scheme of individual images differs from the one shown in Figure 4; this was needed to conduct miR-21 (green), PTEN (red) and Vimentin (blue) expression analysis with Image Pro-Plus software. b) miR-21, PTEN and Vimentin (VIM) images were merged using the combine channels function from cellSens and saved as RGB TIF files. Once on Image Pro, a free shape line trace (line tool profile analysis) was used to quantitate intensity of miR-21, PTEN and VIM expression. Merged RGB may be shifted with respect to raw images to fully display the line trace. Background intensity was subtracted from the intensity values and intensity values were normalized setting the point with maximum intensity at 100 and calculating other value in relation to this reference. Square dot indicates the beginning of the line profile reading and it corresponds to the most left value of the graph panels.



Supplementary Figure 6. Co-detection of microRNAs, ribosomal RNA and protein markers in breast tissue. Serial 4-µm FFPE tumor tissue sections of breast tissue were to standard ISH assay using FAM2X-tagged probe against miR-126, BrdU2X-tagged probe against miR-205, DIG2X-tagged against let-7a and Bio2X-tagged probes against 18S rRNA. miR-126, miR-205, let-7a and 18S rRNA signal was revealed by sequential TSA reactions with FITC-tyramine (green), Rhodamine-tyramine (orange), AMCA-tyramine (blue) and Dylight594 (red) substrates. After a HIER with citrate, Vimentin (VIM) expression was revealed by TSA reaction with Dylight680 (magenta). Matched normal and tumor raw fluorescent images for indicated RNA and protein markers were captured with the same exposure and gain settings.



Supplementary Figure 7. miR-21 and PTEN expression in matched normal and tumor tissues. a) Matched normal and tumor tissue of indicated organs were subject to our standard ISH assay to detect miR-21 expression using a FAM2X-tagged probe. A TSA reaction with green fluorochrome substrate (FITC-tyramine) was carried out to reveal miR-21 expression. After HIER with citrate, PTEN expression was revealed with red fluorochrome substrate (Rhodamine-tyramine). Matched normal and tumor raw fluorescent images for miR-21 and PTEN were captured with the same exposure and gain settings for each specific organ. These are an independent set of specimens that those shown in other figures.

| RNA | T _m | Probe Sequence | °Cª | SSC⁵ | Expression ^c |
|---------------------------------|--------------------|---|----------------|----------------------|--|
| let-7a | 78.3 | AA+CTA+TA+CAA+CC+TA+CTA+CCT+CA | 50 | 0.5X | various |
| miR-21 | 73.8 | T+CAA+CAT+CA+GT+CTG+ATA+AG+CTA | 45 | 0.5X | TAFs, cancer cells |
| miR-24 | 80 | CT+GTT+CCT+GCT+GAA+CTG+AGC+CA | 37 | 0.5X | various |
| mir-34a | 80 | A+CAA+CCA+GCT+AAG+ACA+CTG+CCA | 50 | 0.1X | epithelia, others |
| miR-34c-5p | 79 | GCA+ATC+AGC+TAA+CTA+CA+CTG+CCT | 37 | 0.5X | epithelia |
| miR-125b | 77.2 | TC+ACA+AGT+TAG+GGT+CTC+AGG+GA | 45 | 0.5X | fibroblasts, epithelia |
| miR-126 | 73.4 | CG+CAT+TAT+TAC+TCA+CGG+TAC+GA | 45 | 0.5X | endothelia |
| miR-141 | 75 | C+CAT+CTT+TAC+CA+GA+CA+GTG+TTA | 37 | 0.5X | epithelia |
| miR-143 | 73.4 | GA+GCT+ACA+GTG+CTT+CAT+CT+CA | 50 | 0.5X | various |
| miR-145 | 79 | AAG+ G GA+TTC+CTG+GGA+AAA+CTG+GAC | 50 | 0.1X | smooth muscle cells |
| miR-155 | 74 | T+TA+AT+GCT+AAT+CGT+GAT+AG+GG+GT | 50 | 0.5X | leukocytes |
| miR-196 | 76.8 | CC+CAA+CAA+CAT+GA+AA+CT+AC+CTA | 37 | 0.5X | cancer cells |
| miR-200b | 73.7 | GT+CAT+CAT+TA+CCA+GG+CA+GTA+TTA | 37 | 0.5X | various |
| miR-205 | 75.6 | CA+GAC+TCC+GGT+GGA+ATG+AAG+GA | 50 | 0.1X | myo/basal epithelia |
| miR-214 | 80.4 | CT+GCC+TGT+CTG+TGC+CTG+CTGT | 50 | 0.1X | various |
| miR-221 | 80.8 | GA+ A A+ C C+ C AG+ C AGA+ C AA+ T GT+ A G+ C T | 37 | 0.5X | various |
| miR-375 | 75 | TC+ACG+CGA+GCC+GAA+CGA+ACA+AA | 45 | 0.5X | endocrine cells |
| miR-451 | 76.7 | AAA+CT+CAG+TA+AT+GG+TAA+CG+GT+TT | 45 | 0.5X | erythrocytes |
| U6 snRNA | 75 | CGTGTCATCCTTGCGCAGGGGGCCATGCTAATCTTCTCTGT | 50 | 0.5X | ubiquitous |
| 18S rRNA | 79.3 | GGGCAGACGTTCGAATGGGTCGTCGCCGCCACGGG | 50 | 0.5X | ubiquitous |
| miR-451 U6 snRNA 18S rRNA | 76.7 75 79.3 | AAA +C T +C AG +T A +A T +G G +T AA +C G +G T+ T T CGTGTCATCCTTGCGCAGGGGGCCATGCTAATCTTCTCTGT GGGCAGACGTTCGAATGGGTCGTCGCCGCCACGGG | 45 50 50 | 0.5X 0.5X 0.5X | erythrocytes ubiquitous ubiquitous |

Table S1. miRNA probe sequences and hybridization conditions. Sequences of LNA-modified DNA probes against indicated miRNA or other non-coding RNA species. "+N" denotes LNA-modified nucleotide. ^aIncubation temperature of hybridization and washing steps. ^bConcentration of SSC in washing steps. ^cSummary of predominant cell type(s) of miRNA expression in normal and tumor tissues from breast, colon, lung, pancreas and/or prostate. "Various" indicates a complex pattern of expression as regards to the cell type(s) in which the miRNA is expressed and/or the direction of miRNA expression changes within cancer cells.

| Epitope | Source | Dilution | Retrieval | Clone name | Cat# | Company |
|---------------------|------------|----------|-----------|---------------------|----------------|--------------------------|
| Amylase | Mouse | 1:200 | AR1 | G-10 | sc-46657 | Santa Cruz Biotechnology |
| CK5/6 | Mouse | 1:50 | AR1+ | | CM105C | Biocare |
| CK7 | Mouse | 1:100 | 0 | OV-TL12/30 | MU255-UC | Biogenex |
| CK8/18 | Mouse | 1:50 | 0 | 5D3 | MU131-UC | Biogenex |
| CK14 | Mouse | 1:100 | AR2 | | CM185B | Biocare |
| CK19 | Mouse | 1:200 | 0 | RCK108 | MU246-UC | Biogenex |
| CK20 | Mouse | 1:200 | 0 | Ks20.8 | M7019 | Dako |
| CD31 | Mouse | 1:100 | AR1 | JC70A | M0823 | Dako |
| CD45 | Mouse | 1:100 | AR1 | 2D1 | 560274 | BD Pharmingen |
| E-cadherin | Rabbit | 1:200 | AR1 | 24E10 | 3195 | Cell signaling |
| ER | Mouse | 1:10 | AR1+ | 1D5 | MU272-UCE | Biogenex |
| Glucagon | Mouse | 1:500 | AR1 | K79bB10 | ab10988 | Abcam |
| HER2 | Mouse | 1:20 | AR1+ | CB11 | MU134-UC | Biogenex |
| Insulin | Guinea pig | 1:500 | 0 | | A564 | Dako |
| Ki-67 | Mouse | 1:200 | AR1 | MM1 | NCL-L-Ki67-MM1 | Novocastra |
| рАКТ | Rabbit | 1:50 | 0 | 736E11 | 3787 | Cell signaling |
| P53 | Mouse | 1:200 | AR1 | DO-1 | sc-126 | Santa Cruz Biotechnology |
| PCNA | Mouse | 1:300 | AR1+ | PC10 | NCL-L-PCNA | Novocastra |
| PR | Mouse | 1:25 | AR1+ | PR88 | MU328-UC | Biogenex |
| PTEN | Rabbit | 1:100 | AR1 | 138G6 | 9559 | Cell signaling |
| Smooth muscle actin | Mouse | 1:500 | 0 | 1A4 | MU128-UC | Biogenex |
| Somatostatin | Rabbit | 1:100 | 0 | | 18-0078 | Zymed |
| Tubulin | Rat | 1:1000 | 0 | YL1/2 | Ab6160-100 | Abcam |
| Vimentin | Mouse | 1:1000 | AR1 | V9 | MU074-UC | Biogenex |
| Epitope | Source | Dilution | Retrieval | Name (clone) | Cat# | Company |
| Biotin | N/A | 1:7000 | 0 | Streptavidin/HRP | SA100-01 | Invitrogen |
| BrdU | Rat | 1:1000 | 0 | Anti-BrdU | NB500-169 | Novus Biologicals |
| DIG | Sheep | 1:1000 | 0 | Anti-DIG/HRP | 11207733910 | Roche |
| FITC,FAM | Rabbit | 1:200 | 0 | Anti-FITC/HRP | P5100 | Dako |
| Guinea pig Fc | Goat | 1:500 | 0 | Anti-guinea pig/Cy3 | 106-165-003 | Jackson ImmunoResearch |
| Goat Fc | Rabbit | 1:500 | 0 | Anti-goat/HRP | 172-1034 | Biorad |
| Mouse Fc | Goat | 1:500 | 0 | Anti-mouse/HRP | 170-6516 | Biorad |
| Rat Fc | Goat | 1:1000 | 0 | Anti-rat/HRP | 401416 | Calbiochem |
| Rabbit Fc | Goat | 1:500 | 0 | Anti-rabbit/HRP | 170-6515 | Biorad |
| Sheep Fc | Rabbit | 1:500 | 0 | Anti-sheep/HRP | 402100 | Calbiochem |

Table S2. Antibody conditions. Protein detection is compatible with previous ISH procedure without further treatment (0) or followed by heat-induced epitope retrieval by 20 min incubation in 95°C water bath with pre-warmed Citrate-based antigen unmasking solution (AR1; Vector Laboratories, H3300) or Reveal (AR2; Biocare Medical, RV1000MMRTU), or by heating in decloaking chamber (Biocare Medical, DC2002-CE) with default program (1 min at 121 °C) with Citrate-based antigen unmasking solution (AR1+).

Note: Staining with COX-2 antibody (Cell signaling, cat#4842) and Ki-67 (Abcam, ab833) was not compatible with ISH procedure due to intense non-specific background signal.

| Substrate | Dilution (miRNA) | Incubation time (miRNA) | Dilution (protein) | Incubation time (protein) | |
|---------------------------|------------------|-------------------------|--------------------|---------------------------|--|
| Alexa Fluor 647 | Not determined | Not determined | 1:100-1:200 | 15 min (10-30 min) | |
| AMCA | 1:300-1:500 | 15 min (10-30 min) | 1:500-1:1000 | 10 min (5-20 min) | |
| Dylight405 | 1:50-1:100 | 15 min (10-30 min) | 1:100-1:200 | 15 min (10-30 min) | |
| Dylight594 | 1:50-1:100 | 15 min (10-30 min) | 1:100-1:200 | 15 min (10-30 min) | |
| Dylight649 | Not determined | Not determined | 1:100-1:200 | 15 min (10-30 min) | |
| Dylight680 | Not determined | Not determined | 1:100-1:200 | 15 min (10-30 min) | |
| FITC | 1:100-1:200 | 15 min (10-30 min) | 1:200-1:400 | 10 min (5-20 min) | |
| Rhodamine | 1:500 | 15 min (10-30 min) | 1:1000 | 10 min (5-20 min) | |
| Reagent | | Cat # | Co | mpany | |
| Alexa Fluor 647-NHS ester | | A-20006 | Invitrogen | | |
| AMCA-NHS ester | | 33005 | Pierce | | |
| Dylight405-NHS ester | | 46400 | Pierce | | |
| Dylight594-NHS e | ster | 46408 | Pierce | | |
| Dylight649-NHS ester | | 46415 | Pierce | | |
| Dylight680-NHS ester | | 46418 | Pie | erce | |
| Fluorescein-NHS ester | | 46100 | Pie | erce | |
| Rhodamine-NHS ester | | 46102 | Pie | erce | |
| Tyramine hydrochloride | | T2879 | Sig | Ima | |
| Dimethyl formamie | de (DMF) | D4551 | Sigma | | |
| Triethylamine (TE | A)* | T0886 | Sigma | | |

Table S3. Preparation of tyramide substrates and conditions for TSA reaction for microRNA and protein detection. Preparation of these reagents is based on Davidson protocol for FITC tyramide substrate (<u>http://www.xenbase.org/other/static/methods/FISH/fluorescein_tyramide.jsp</u>, but see also Vize et al. 2009(1) for additional information. *Please note that for acetylation reaction we used triethanolamine, which is a different compound.

Coupling Reaction:

Work under a chemical hood in a dry environment. If stock reagents are frozen, let equilibrate at room temperature and wipe with a paper towel the tubes to remove any moisture. Use only fresh reagents:

- Dissolve fluorochrome-NHS ester at 10 mg/mL stock in DMF.
- Prepare DMF-TEA solution (100:1 v/v) as needed.
- Dissolve the tyramine at 10 mg/mL in DMF-TEA.

- Add needed volume of tyramide/DMF-TEA into fluorochrome-NHS ester/DMF to achieve a molar ratio of 1:1.

- Incubate in dark at room temperature for 2 hours.

- Add 1 volume of 100% ethanol and store at -20°C. Use as indicated above.

Note: AMCA-NHS ester (blue), Fluorescein-NHS ester (green), Rhodamine-NHS ester (red) provide a convenient and economic fluorochrome choice for a three-color co-staining scheme using conventional fluorescence microscopy. A series of DyLight-NHS (Pierce) or Alexa Fluor-NHS (Invitrogen) fluorescent compounds with distinct excitation/emission spectra allow for of additional colors. In our hand, miRNA detection with commercially available TSA kits was less sensitive than with our reagents and protocol; this could be due to considerable differences in concentration between the fluorescent substrates in Alexa Fluor[®] TSA[™] kit (Invitrogen) and TSA[™] Plus System (PerkinElmer) and our in-house synthesized fluorochromes (data not shown). In our hand, miRNA detection with commercially available TSA kits was less sensitive than with our reagents and protocol; this could be due to considerable differences in concentration between the fluorescent substrates in Alexa Fluor[®] TSA[™] kit (Invitrogen) and TSA[™] Plus System (PerkinElmer) and our in-house synthesized fluorochromes in concentration between the fluorescent substrates differences in concentration between the fluorescent substrates and protocol; this could be due to considerable differences in concentration between the fluorescent substrates in Alexa Fluor[®] TSA[™] kit (Invitrogen) and TSA[™] Plus System (PerkinElmer) and our in-house synthesized fluorochromes (data not shown).

Supplementary References

 Vize PD, McCoy KE, Zhou X. Multichannel wholemount fluorescent and fluorescent/chromogenic in situ hybridization in Xenopus embryos. Nat Protoc 2009;4(6):975-83.